In filings the company states it has or will soon have patents for their Adenosine drug platform all around the world. It also owns outright the patent for a thapsigargin based tumor targeting drug Mipsagargin which has orphan drug designation thru 2034. Mipsagargin has completed PH I and II trials with certain success and well tolerated side effects. Also in the filings the company states that it is close to a IND application for novel drug RT-AR001 followed up by approval and possible clinical trials. Also in the filings it was stated that NSPX has incurred 60+ million in losses since 2003 to get to this point in development. This point of development is a market cap of 3.4 million (peanuts), 515 million shares outstanding and a PPS of 3/4 of a penny. Go figure. Let's think that this upcoming IND can put a jolt into what has been a lackluster year for nspx.
Market Data 
Markets 
AI
